SCHEMBL3970186

SCHEMBL3970186

COc1cc(NC(=O)OC(C)(C)C)c(Cl)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
GAA P10253 3/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP1B1 Q16678 1/20 0.40
ABCB1 P08183 1/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
FGFR3 P22607 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ATR Q13535 1/20 0.39
NR1I2 O75469 1/20 0.38
TP53 P04637 2/20 0.38
LPAR1 Q92633 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
ACAT1 P24752 1/20 0.38
SOAT1 P35610 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768199 0.84 GAA (0.41) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL4405601 0.83 GAA (0.40) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL29514038 0.83 GAA (0.40) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL4768748 0.83 CYP1A1 (0.43) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL3976468 0.80 CYP1A1 (0.44) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL374670 0.80 HSD17B1 (0.48) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL2589170 0.79 ALDH1A1 (0.63) ALDH1A1GAACYP1A1CYP1A2CYP1B1
SCHEMBL29991362 0.79 GAA (0.60) ALDH1A1GAACYP1A2MAPTMEN1
SCHEMBL115661 0.79 GAA (0.60) ALDH1A1GAACYP1A2MAPTMEN1
SCHEMBL28184008 0.79 ATR (0.48) ALDH1A1GAACYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501425-B1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation WARNER LAMBERT COMPANY (US) 2009-03-10 US disclosed
EP-1080092-B1 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER LAMBERT CO (US) 2008-07-23 EP disclosed
EP-1801112-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation Warner-Lambert Company LLC (US) 2007-06-27 EP disclosed
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation DOBRUSIN ELLEN MYRA (US) 2004-03-04 US disclosed
EP-1080092-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 2001-03-07 EP disclosed
WO-1999061444-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation CCNI, CCNH, CCNA1 ALDH1A1 2575/4885GAA 3637/4885CYP1A1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.